advertisement
Abstract #8677 Published in IGR 5-1
Influence of dorzolamide on corneal endothelium
Inoue K; Okugawa K; Oshika T; Amano SJapanese Journal of Ophthalmology 2003; 47: 129-133
PURPOSE: To evaluate the influence of topical 1% dorzolamide treatment for three months on the endothelial morphology and the thickness of the cornea. METHODS: The corneal endothelium was investigated in 21 glaucoma patients (29 eyes) who received topical 1% dorzolamide treatment for three months. Intraocular pressure (IOP), corneal endothelium, and central corneal thickness (CCT) were measured before and three months after topical dorzolamide treatment. The relationship between the endothelial cell density loss or the CCT increase, and factors such as the history of previous intraocular surgery, the presence of type II diabetes mellitus, type of glaucoma, IOP before treatment (above or below 20 mmHg), or the kinds of eye drops used before dorzolamide treatment were evaluated. RESULTS: The endothelial cell density, coefficient of variation of cell area, and percentage of hexagonal cells did not change significantly. The CCT after treatment (537 ± 34 m) was significantly increased over that before treatment (530 ± 33 m). There was no significant relation of endothelial cell loss or CCT increase to any of the above factors. CONCLUSIONS: Topical 1% dorzolamide treatment increases CCT and does not affect corneal endothelial morphology.
Dr. K. Inoue, Inoue Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
